More people experienced high blood pressure in response to the COVID-19 pandemic compared to before, according to new research from chronic care management company Livongo.
The study looked at the proportion of Livongo members who had high blood pressure before and during the pandemic, specifically covering the time between mid-September of 2019 and mid-August of 2020.
The data does not support a...
(Photo by Kimberly White/Getty Images for TechCrunch)
Last week the digital health world was taken by storm when news broke that virtual health giant Teladoc was set to acquire chronic care management platform Livongo in a whopping $18.5 billion deal.
Livongo has had quite a year in a half. Last July, it went public with a listing price of $28 a share. At the time of the acquisition, each share was valued at roughly $159. Its news has also included...
The MobiHealthNews team members — host Jonah Comstock, Managing Editor Laura Lovett and Associate Editor Dave Muoio — sit down to unpack the major shakeup that hit the digital health markets this week when telemedicine giant Teladoc announced its plan to merge with chronic condition management success story Livongo. We talk details, motivations and implications of this digital health mega-company...
Shortly before news broke that Teladoc was set to acquire Livongo, the chronic disease management company announced its quarterly earnings results. On Aug. 5 it announced that its second quarter total revenue came in at $91.9 million, which was up 125% YoY. The company reported a GAAP gross margin of 76.6% and non-GAAP gross margin of 77.3%.
The company attributed the gains to its growing...
Digital health titans Teladoc Health and Livongo are merging under the Teladoc name. The deal values the 12-year-old digital chronic care-management company Livongo at $18.5 billion.
Teladoc CEO Jason Gorevic is expected to remain at the helm of the soon-to-be joint company, while Livongo’s CEO and founder Glen Tullman will be taking up a seat on the Teladoc board.
Teladoc plans to buy Livongo...
A retrospective analysis of more than 2,000 Livongo Diabetes Prevention Program (DPP) participants found an average weight loss of 5.1% from baseline after 12 months, and 6.6% among those who designated as high engagers.
The study, conducted by Livongo and published in BMJ Open Diabetes Research & Care, honed in on the relationships between specific program behaviors and program engagement...
The healthcare startup market has always had the unique challenge of selling its innovations almost exclusively to major businesses. Although recent years have seen a rise in digital health offerings focused on patient satisfaction, if not on selling their product directly to the consumer, the reality of the industry is that insurers, pharmacy benefit managers, large employers, health systems,...
This quarter Dexcom raked in $405 million in revenue, compared to $280.5 million in 2019’s Q1. This represents a 44% increase year over year (YoY), and beats the company's revenue goal by $46.7 million. Dexcom attributes its success to its growing user rate.
The gross profits from Q1 were $258.7 million. However, operating expenses have increased, coming in at $215.4 million in 2020 Q1, versus $...
A number of digital health companies have seen their businesses grow amid the COVID-19 crisis, and so far Livongo Health appears to be no exception. The company announced strong quarterly results headlined by revenue growth and a record number of client launches.
Taking new agreements and the prospect of continued demand for virtual services into account, the company said that it has raised its...
It was another strong quarter for the ever-growing Livongo Health, which yesterday reported to investors a 137% rise in year-over-year Q4 revenue from $21.2 million to $50.2 million. Full-year revenues followed a similar path, growing 149% from $68.4 million in 2018 to $169.9 million in 2019.
“Livongo finished the year with excellent momentum, exceeding all of our guidance metrics, achieving...
